| Peer-Reviewed

Antiproliferative Activity of a Dietary Supplement on Estrogen Receptor Positive and Negative Human Breast Adenocarcinoma Cell Lines

Received: 10 February 2014     Published: 30 March 2014
Views:       Downloads:
Abstract

A commercial food supplement called Citozym (CIZ), was tested for antiproliferative activity against estrogen receptor (ER)-positive MCF-7 and (ER)-negative BT-20 human breast cancer cells, performing two independent experiments using SRB assay. A CIZ concentration of 100mg/mL, showed the most potent antiproliferative activity for cells in a potential range for further investigation on estrogen-insensitive breast cancer therapy

Published in Cancer Research Journal (Volume 2, Issue 2)
DOI 10.11648/j.crj.20140202.13
Page(s) 29-32
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2014. Published by Science Publishing Group

Keywords

Food Supplements, (ER)+/(ER)- Breast Cancers, Cancer Cell Survival

References
[1] Carter B. S., Beaty T. H., Steinberg G. D., Childs B. & Walsh P. C. Mendelian inheritance of familial prostate cancer. Proc. Natl. Acad. Sci. U.S.A. 1992; 89: 3367–3371.
[2] Muraca L, Leung D, Clark A, Beduz MA, Goodwin P. Breast cancer survivors: taking charge of lifestyle choices after treatment. Eur J Oncol Nurs. 2011;15(3):250-253.
[3] Meiyanto E, Hermawan A, Anindyajati. Natural products for cancer-targeted therapy: citrus flavonoids as potent chemopreventive agents.Asian Pac J Cancer Prev. 2012;13(2):427-436.
[4] Arcangeli S., Pinzi V., Arcangeli G. Epidemiology of prostate cancer and treatment remarks. World J. Radiol. 2012;4:241–246.
[5] Gorrini C, Harris IS, Mak TW. Modulation of oxidative stress as an anticancer strategy.Nat Rev Drug Discov. 2013;12(12):931-947.
[6] Vera-Ramirez L, Sanchez-Rovira P, Ramirez-Tortosa MC, Ramirez-Tortosa CL, Granados-Principal S, Lorente JA, Quiles JL.Free radicals in breast carcinogenesis, breast cancer progression and cancer stem cells. Biological bases to develop oxidative-based therapies.Crit Rev Oncol Hematol. 2011;80(3):347-368.
[7] Antonelli F & Beninati S. Enhanced survival of B16-F10 melanoma tumour-bearing C57BL6/N mice treated with a mixture of antioxidants in: Recent Res Devel in Life Sci. 2011;5:51-60 Research Signpost, Trivandrum India
[8] Keawpradub N, Amooquaye E.E, Burke PJ, Houghton PJ. Cytotoxic activity of indole alkaloids from Alstonia macrophylla. Planta Medica 1999;65: 311–315.
[9] Skehan P, Storeng R, Scudiero D, Monks A, McMahon I, Vistica D, Waren JT, Bokesch H, Kenney S, Boyd MR. New colorimetric cytotoxicity assay for anticancer drug screening. Journal of National Cancer Institute. 1990: 82:1107–1112.
[10] Lipsett MB. Prospects in endocrinology for chemotherapy. Cancer Res. 1969;29(12):2408-2411.
[11] Jensen EV, and Jacobson H. I. Basic Guides to the Mechanism of Estrogen Action. Recent Progr. Hormone Res.1962;18: 387-408.
[12] Cuzick J. IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole. Expert Rev Anticancer Ther. 2008;8(9):1377-1385.
[13] Klepin HD, Geiger AM, Bandos H, Costantino JP, Rapp SR, Sink KM, Lawrence JA, Atkinson HH, Espeland MA. Cognitive Factors Associated with Adherence to Oral Antiestrogen Therapy: Results from the Cognition in the Study of Tamoxifen and Raloxifene (Co-STAR) Study.Cancer Prev Res (Phila). 2014;7(1):161-168.
[14] Osborne CK, McGuire WL.Therapy for cancer of the breast. Current status of steroid hormone receptors. West J Med. 1979;130(5):401-407.
Cite This Article
  • APA Style

    Torricelli Piera, Antonelli Francesco, Ferorelli Pasquale, De Martino Angelo, Shevchenko Anna, et al. (2014). Antiproliferative Activity of a Dietary Supplement on Estrogen Receptor Positive and Negative Human Breast Adenocarcinoma Cell Lines. Cancer Research Journal, 2(2), 29-32. https://doi.org/10.11648/j.crj.20140202.13

    Copy | Download

    ACS Style

    Torricelli Piera; Antonelli Francesco; Ferorelli Pasquale; De Martino Angelo; Shevchenko Anna, et al. Antiproliferative Activity of a Dietary Supplement on Estrogen Receptor Positive and Negative Human Breast Adenocarcinoma Cell Lines. Cancer Res. J. 2014, 2(2), 29-32. doi: 10.11648/j.crj.20140202.13

    Copy | Download

    AMA Style

    Torricelli Piera, Antonelli Francesco, Ferorelli Pasquale, De Martino Angelo, Shevchenko Anna, et al. Antiproliferative Activity of a Dietary Supplement on Estrogen Receptor Positive and Negative Human Breast Adenocarcinoma Cell Lines. Cancer Res J. 2014;2(2):29-32. doi: 10.11648/j.crj.20140202.13

    Copy | Download

  • @article{10.11648/j.crj.20140202.13,
      author = {Torricelli Piera and Antonelli Francesco and Ferorelli Pasquale and De Martino Angelo and Shevchenko Anna and Beninati Simone},
      title = {Antiproliferative Activity of a Dietary Supplement on Estrogen Receptor Positive and Negative Human Breast Adenocarcinoma Cell Lines},
      journal = {Cancer Research Journal},
      volume = {2},
      number = {2},
      pages = {29-32},
      doi = {10.11648/j.crj.20140202.13},
      url = {https://doi.org/10.11648/j.crj.20140202.13},
      eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.crj.20140202.13},
      abstract = {A commercial food supplement called Citozym (CIZ), was tested for antiproliferative activity against estrogen receptor (ER)-positive MCF-7 and (ER)-negative BT-20 human breast cancer cells, performing two independent experiments using SRB assay. A CIZ concentration of 100mg/mL, showed the most potent antiproliferative activity for cells in a potential range for further investigation on estrogen-insensitive breast cancer therapy},
     year = {2014}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - Antiproliferative Activity of a Dietary Supplement on Estrogen Receptor Positive and Negative Human Breast Adenocarcinoma Cell Lines
    AU  - Torricelli Piera
    AU  - Antonelli Francesco
    AU  - Ferorelli Pasquale
    AU  - De Martino Angelo
    AU  - Shevchenko Anna
    AU  - Beninati Simone
    Y1  - 2014/03/30
    PY  - 2014
    N1  - https://doi.org/10.11648/j.crj.20140202.13
    DO  - 10.11648/j.crj.20140202.13
    T2  - Cancer Research Journal
    JF  - Cancer Research Journal
    JO  - Cancer Research Journal
    SP  - 29
    EP  - 32
    PB  - Science Publishing Group
    SN  - 2330-8214
    UR  - https://doi.org/10.11648/j.crj.20140202.13
    AB  - A commercial food supplement called Citozym (CIZ), was tested for antiproliferative activity against estrogen receptor (ER)-positive MCF-7 and (ER)-negative BT-20 human breast cancer cells, performing two independent experiments using SRB assay. A CIZ concentration of 100mg/mL, showed the most potent antiproliferative activity for cells in a potential range for further investigation on estrogen-insensitive breast cancer therapy
    VL  - 2
    IS  - 2
    ER  - 

    Copy | Download

Author Information
  • Department SPES, University of Molise, Campobasso, Italy

  • Department of Biology, University of Tor Vergata, Rome, Italy

  • Department of Biology, University of Tor Vergata, Rome, Italy

  • Department of Biology, University of Tor Vergata, Rome, Italy

  • People’s Friendship University of Russia, Moscow, Russia

  • Department of Biology, University of Tor Vergata, Rome, Italy

  • Sections